Formulary Watch |

The FDA needs additional time to assess information about proposed risk revaluation mitigation strategy for the treatment for obstructive hypertrophic cardiomyopathy.

Most of the patients with no immune response after the two-dose regimen responded well to a third shot.

ICER’s review indicates that Humira’s price increases are not supported by new clinical evidence.

A reimbursement policy similar to that used for branded and generic drugs would have saved $1.6 billion from 2015 to 2019.

Patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma were more likely to have a COVID-19 breakthrough infection.

Smaller PBMs are rated higher by health plans in terms of satisfaction because of their ability to offer more customized solutions.

The safety labeling for the beta interferons that are used to treat multiple sclerosis have been updated to include warnings about injection site reactions.

Paxlovid, an at-home treatment for COVID-19, reduces illness severity, hospitalizations, and deaths among adults by 89%.

CVS Caremark has removed 10 branded products from its formulary and added about 30 additional products.

The studies conducted to support Verzenio’s most recent approval for the treatment of high-risk early breast cancer provided additional safety data.

The antidepressant fluvoxamine reduced the need for hospitalization in high-risk patients, according to a new study.

UK regulatory authorities approved molnupiravir to treat patients with mild-to-moderate COVID-19.

This Tufts study has found that plans that restrict orphan drugs do so by narrowing the patient population who can receive them.